Amgen's Q2 2013 earnings call highlighted strong performance, with revenue growth and increased guidance.  Management reassured on the company's strategy, emphasizing progress on pipeline programs like PCSK9 and international collaborations.  The call addressed concerns about Medicaid adjustments and potential future competition but overall painted a picture of continued success and investor confidence.

[1]
